Cargando…

Real-world clinical outcomes following treatment intensification with GLP-1 RA, OADs or insulin in patients with type 2 diabetes on two oral agents (PATHWAY 2-OADs)

INTRODUCTION: Most patients with type 2 diabetes require sequential addition of glucose-lowering agents to maintain long-term glycemic control. In this retrospective, observational study, we compared intensification with a glucagon-like peptide-1 receptor agonist (GLP-1 RA), oral antidiabetic drugs...

Descripción completa

Detalles Bibliográficos
Autores principales:	Desouza, Cyrus, Kirk, Andreas R, Mangla, Kamal K, Wolden, Michael L, Lingvay, Ildiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Emerging Technologies, Pharmacology and Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7778743/ https://www.ncbi.nlm.nih.gov/pubmed/33376084 http://dx.doi.org/10.1136/bmjdrc-2020-001830

Ejemplares similares

Treatment Intensification in Type 2 Diabetes: A Real-World Study of 2-OAD Regimens, GLP-1 RAs, or Basal Insulin
por: Blonde, Lawrence, et al.
Publicado: (2018)

R(h)oads to microvesicles
por: Antonyak, Marc A., et al.
Publicado: (2012)

Where do conventional OADs stand
por: Sahay, Rakesh Kumar, et al.
Publicado: (2012)

Outcomes and Treatment Patterns of Adding a Third Agent to 2 OADs in Patients with Type 2 Diabetes
por: Levin, Philip A., et al.
Publicado: (2014)

Glucagon receptor antagonist upregulates circulating GLP-1 level by promoting intestinal L-cell proliferation and GLP-1 production in type 2 diabetes
por: Lang, Shan, et al.
Publicado: (2020)

Superior weight loss with once-weekly semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse events
por: Lingvay, Ildiko, et al.
Publicado: (2020)

Outcomes in GLP-1 RA-Experienced Patients Switching to Once-Weekly Semaglutide in a Real-World Setting: The Retrospective, Observational EXPERT Study
por: Lingvay, Ildiko, et al.
Publicado: (2021)

Gender Differences in Inhaled Pharmacotherapy Utilization in Patients with Obstructive Airway Diseases (OADs): A Population-Based Study
por: Amegadzie, Joseph Emil, et al.
Publicado: (2020)

Long-Term Treatment with Trazodone Once-A-Day (TzOAD) in Patients with MDD: An Observational, Prospective Study
por: Shrashimirova, Milena, et al.
Publicado: (2023)

A Novel Long Noncoding RNA, Lnc-OAD, Is Required for Bone Morphogenetic Protein 2- (BMP-2-) Induced Osteoblast Differentiation
por: Wang, Zonggui, et al.
Publicado: (2021)

Efficacy, safety and cost-effectiveness comparison between U-100 human regular insulin and rapid acting insulin when delivered by V-Go wearable insulin delivery device in type 2 diabetes
por: Mora, Pablo F, et al.
Publicado: (2020)

Enhancement of Vasoreactivity and Cognition by Intranasal Insulin in Type 2 Diabetes
por: Novak, Vera, et al.
Publicado: (2014)

Comparison of weight-based insulin titration (WIT) and glucose-based insulin titration using basal-bolus algorithm in hospitalized patients with type 2 diabetes: a multicenter, randomized, clinical study
por: Zhang, Xiaodan, et al.
Publicado: (2020)

Fabrication and Characteristics of ZnO/OAD-InN/PbPc Hybrid Solar Cells Prepared by Oblique-Angle Deposition
por: Chen, Cheng-Chiang, et al.
Publicado: (2012)

Molecular and pharmacological characterization of insulin icodec: a new basal insulin analog designed for once-weekly dosing
por: Nishimura, Erica, et al.
Publicado: (2021)

Post hoc efficacy and safety analysis of insulin glargine/lixisenatide fixed- ratio combination in North American patients compared with the rest of world
por: Dailey, George, et al.
Publicado: (2019)

DPP4i, thiazolidinediones, or insulin and risks of cancer in patients with type 2 diabetes mellitus on metformin–sulfonylurea dual therapy with inadequate control
por: Wong, Carlos K H, et al.
Publicado: (2020)

Impact of symptomatic upper respiratory tract infections on insulin absorption and action of Technosphere inhaled insulin
por: Levin, Philip A, et al.
Publicado: (2016)

Safety of Nighttime 2-Hour Suspension of Basal Insulin in Pump-Treated Type 1 Diabetes Even in the Absence of Low Glucose
por: Sherr, Jennifer L., et al.
Publicado: (2014)

Addition of a single short-acting insulin bolus to basal insulin-supported oral therapy: a systematic review of data on the basal-plus regimen
por: Seufert, Jochen, et al.
Publicado: (2019)

Restoring Insulin Secretion (RISE): Design of Studies of β-Cell Preservation in Prediabetes and Early Type 2 Diabetes Across the Life Span
Publicado: (2014)

Real-world risk of hypoglycemia-related hospitalization in Japanese patients with type 2 diabetes using SGLT2 inhibitors: a nationwide cohort study
por: Horii, Takeshi, et al.
Publicado: (2020)

Flash glucose monitoring helps achieve better glycemic control than conventional self-monitoring of blood glucose in non-insulin-treated type 2 diabetes: a randomized controlled trial
por: Wada, Eri, et al.
Publicado: (2020)

Lixisenatide is effective and safe as add-on treatment to basal insulin in Asian individuals with type 2 diabetes and different body mass indices: a pooled analysis of data from the GetGoal Studies
por: Feng, Wenhuan, et al.
Publicado: (2021)

HbA1c target achievement in the elderly: results of the Titration and Optimization trial for initiation of insulin glargine 100 U/mL in patients with type 2 diabetes poorly controlled on oral antidiabetic drugs
por: Fritsche, Andreas, et al.
Publicado: (2019)

Effect of dapagliflozin on 24-hour glycemic variables in Japanese patients with type 2 diabetes mellitus receiving basal insulin supported oral therapy (DBOT): a multicenter, randomized, open-label, parallel-group study
por: Kudo, Akihiro, et al.
Publicado: (2023)

Improved diabetes medication convenience and satisfaction in persons with type 2 diabetes after switching to insulin glargine 300 U/mL: results of the observational OPTIN-D study
por: Wieringa, Thomas H, et al.
Publicado: (2018)

Effect of treatment with exenatide and pioglitazone or basal-bolus insulin on diabetic neuropathy: a substudy of the Qatar Study
por: Ponirakis, Georgios, et al.
Publicado: (2020)

Inhaled Formoterol Diminishes Insulin-Induced Hypoglycemia in Type 1 Diabetes
por: Belfort-DeAguiar, Renata D., et al.
Publicado: (2015)

Supervised learning reveals circulating biomarker levels diagnostic of hepatocellular carcinoma in a clinically relevant model of non-alcoholic steatohepatitis; An OAD to NASH
por: Hwang, Anne, et al.
Publicado: (2018)

Oral administration of NPC43 counters hyperglycemia and activates insulin receptor in streptozotocin-induced type 1 diabetic mice
por: Lan, Zi-Jian, et al.
Publicado: (2020)

Real-world weight change, adherence, and discontinuation among patients with type 2 diabetes initiating glucagon-like peptide-1 receptor agonists in the UK
por: Weiss, Tracey, et al.
Publicado: (2022)

Controlling glycemic variability in people living with type 1 diabetes receiving insulin glargine 300 U/mL (Gla-300)
por: Mader, Julia K, et al.
Publicado: (2022)

Better TIR, HbA1c, and less hypoglycemia in closed-loop insulin system in patients with type 1 diabetes: a meta-analysis
por: Jiao, Xiaojuan, et al.
Publicado: (2022)

Deletion of GPR21 improves glucose homeostasis and inhibits the CCL2-CCR2 axis by divergent mechanisms
por: Riddy, Darren M, et al.
Publicado: (2021)

Acute Metabolic Effects of Exenatide in Patients With Type 1 Diabetes With and Without Residual Insulin to Oral and Intravenous Glucose Challenges
por: Ghazi, Tara, et al.
Publicado: (2014)

Response evaluation of SGLT2 inhibitor therapy in patients with type 2 diabetes mellitus using (18)F-FDG PET/MRI
por: Rasul, Sazan, et al.
Publicado: (2020)

Successful outcomes using Long Acting Buprenorphine (LAB - Buvidal) to treat Codeine, Tramadol and other Opioid Analgesia Dependencies (OAD) in Wales during the Pandemic
por: Melichar, J., et al.
Publicado: (2022)

Preexisting Insulin Autoantibodies Predict Efficacy of Otelixizumab in Preserving Residual β-Cell Function in Recent-Onset Type 1 Diabetes
por: Demeester, Simke, et al.
Publicado: (2015)

Secondary metformin monotherapy failure in individuals with type 2 diabetes mellitus
por: Weiss, Tracey, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_tkb0u0tpdbtgpeno0v0n3ev83q